Stabilized nitric oxide - primary amine complexes useful as cardiovascular agents
AssigneeThe United States of America as represented by the Department of Health and Human Services
InventorLarry K. Keefer
Life of this patent
Estimating the term…
Abstract
A method of treating cardiovascular disorders in a mammal, by administering to said mammal an effective amount of a compound of the formula: [R--N(H)N(NO)O--].sub.y X wherein R is loweralkyl, aryl, arylalkyl, or cycloalkyl, any of which R groups may be optionally substituted by one to three substituents selected from the group consisting of: halo, hydroxyl, alkoxy, amino, amido, formyl, carboxyl, or nitro; and wherein X is a pharmaceutically acceptable cation, a pharmaceutically acceptable metal center, or a pharmaceutically acceptable organic group selected from loweralkyl, acyl or amido, and Y is 1 to 3 consistent with the valence of X. Pharmaceutical compositions containing the compounds are also provided.
Claims20
A method of treating hypertension, wherein said method comprises administering to a mammal, in need thereof, a therapeutically effective amount of a compound of the formula:
- [R--N(H)N(NO)O--].sub.y X
- wherein:
- R is C.sub.3-8 lower alkyl, phenyl, benzyl, or C.sub.3-8 cycoloalkyl, any of which R groups may be substituted by one to three substituents, same or different, selected from the group consisting of halo, hydroxy, C.sub.1-8 alkoxy, --NH.sub.2, --C(O)NH.sub.2, --CH(O), --C(O)OH and --NO.sub.2 :
- X is a pharmaceutically acceptable cation,
- a pharmaceutically acceptable metal center, or
- a pharmaceutically acceptable organic group selected from the group consisting of C.sub.1-8 lower alkyl, --C(O)CH.sub.3 and --C(O)NH.sub.2 ;
- and
- Y is one to three, consistent with the valence of X.
A pharmaceutical composition comprising:
- (I) a therapeutically effective hypertension treating amount of a compound of the formula:
- [R--N(H)N(NO)O--].sub.y X
- wherein:
- R is C.sub.3-8 lower alkyl, phenyl, benzyl, or C.sub.3-8 cycloalkyl, any of which R groups may be substituted by one to three substituents, same or different, selected from the group consisting of halo, hydroxy, C.sub.1-8 alkoxy, --NH.sub.2, --C(O)NH.sub.2, --CH(O), --C(O)OH and --NO.sub.2 :
- X is a pharmaceutically acceptable cation, a pharmaceutically acceptable metal center, or a pharmaceutically acceptable organic group, selected from the group consisting of C.sub.1-8 lower alkyl, --C(O)CH.sub.3 and --C(O)NH.sub.2 ;
- Y is one to three, consistent with the valence of X;
- and
- (II) a pharmaceutically acceptable carrier therefor.
Dependencies are inferred from the claim text.